ATS Stock Analysis: ATS | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 2.685m USD | 12M Return: -6.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.08M
Qual. Beats: 0
Rev. Trend: -27.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ATS Corporation is a global provider of automated manufacturing and assembly systems, offering end-to-end services that span pre-automation consulting (discovery, simulation, and total cost of ownership modeling), system design, build and commissioning, contract manufacturing, and post-installation support including training, preventive maintenance, and retooling. The company also develops software and digital solutions, such as connected factory floor management systems that use real-time machine data to reduce downtime and improve productivity.
Its customer base is diversified across multiple end markets, including life sciences, transportation and mobility, consumer products, food and beverage, electronics, nuclear, packaging, warehousing and distribution, and energy. The business model is differentiated by its full lifecycle approach, combining one-time project revenue with recurring aftermarket services, which are typically higher margin and provide more predictable cash flow over the life of an installed system.
Founded in 1978 and headquartered in Cambridge, Canada, the company is listed on the NYSE under the ticker ATS following its January 2016 IPO, and was renamed ATS Corporation in November 2022 from ATS Automation Tooling Systems Inc. It sits within the industrial machinery and components sub-industry, a segment benefiting from long-term trends in manufacturing reshoring, labor shortages, and demand for digitalized production lines.
- Life sciences demand accelerates order growth and margins
- EV battery automation orders surge across transportation segment
- BioVectra CDMO acquisition expands recurring revenue base
| Net Income: 71.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 10.17 > 1.0 |
| NWC/Revenue: 22.48% < 20% (prev 30.79%; Δ -8.31% < -1%) |
| CFO/TA 0.10 > 3% & CFO 448.3m > Net Income 71.6m |
| Net Debt (1.31b) to EBITDA (357.6m): 3.65 < 3 |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.0m) vs 12m ago 0.12% < -2% |
| Gross Margin: 28.62% > 18% (prev 25.53%; Δ 3.10% > 0.5%) |
| Asset Turnover: 66.33% > 50% (prev 54.81%; Δ 11.52% > 0%) |
| Interest Coverage Ratio: 2.03 > 6 (EBIT TTM 203.6m / Interest Expense TTM 100.3m) |
| A: 0.15 (Total Current Assets 1.71b - Total Current Liabilities 1.04b) / Total Assets 4.34b |
| B: 0.17 (Retained Earnings 722.6m / Total Assets 4.34b) |
| C: 0.05 (EBIT TTM 203.6m / Avg Total Assets 4.48b) |
| D: 0.69 (Book Value of Equity 1.78b / Total Liabilities 2.56b) |
| Altman-Z'' = 2.59 = A |
| DSRI: 0.66 (Receivables 994.4m/1.28b, Revenue 2.97b/2.53b) |
| GMI: 0.89 (GM 25.53% / 28.62%) |
| AQI: 1.05 (AQ_t 0.51 / AQ_t-1 0.49) |
| SGI: 1.17 (Revenue 2.97b / 2.53b) |
| TATA: -0.09 (NI 71.6m - CFO 448.3m) / TA 4.34b) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at USD 27.24 with a total of 143,403 shares traded. Over the past week, the price has changed by -5.35%, over one month by -0.26%, over three months by -10.19% and over the past year by -6.07%.
Current recommended Stop Loss: 25.80 (which is 5.3% or 1.3 ATR below the current price).
ATS has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold ATS.
- StrongBuy: 1
- Buy: 5
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 35 | 28.5% |
Market Cap CAD = 3.81b (2.69b USD * 1.4196 USD.CAD)
P/E Trailing = 54.2745
P/E Forward = 21.2766
P/S = 0.9032
P/B = 2.1443
Revenue TTM = 2.97b CAD
EBIT TTM = 203.6m CAD
EBITDA TTM = 357.6m CAD
Long Term Debt = 1.27b CAD (from longTermDebt, last quarter)
Short Term Debt = 42.1m CAD (from shortTermDebt, last quarter)
Debt = 1.59b CAD (from shortLongTermDebtTotal, last quarter) + Leases 154.7m
Net Debt = 1.31b CAD (calculated: Debt 1.59b - CCE 285.0m)
Enterprise Value = 5.12b CAD (3.81b + Debt 1.59b - CCE 285.0m)
Interest Coverage Ratio = 2.03 (Ebit TTM 203.6m / Interest Expense TTM 100.3m)
EV/FCF = 13.05x (Enterprise Value 5.12b / FCF TTM 392.2m)
FCF Yield = 7.66% (FCF TTM 392.2m / Enterprise Value 5.12b)
FCF Margin = 13.20% (FCF TTM 392.2m / Revenue TTM 2.97b)
Net Margin = 2.41% (Net Income TTM 71.6m / Revenue TTM 2.97b)
Gross Margin = 28.62% ((Revenue TTM 2.97b - Cost of Revenue TTM 2.12b) / Revenue TTM)
Gross Margin QoQ = 25.20% (prev 29.44%)
Tobins Q-Ratio = 1.18 (Enterprise Value 5.12b / Total Assets 4.34b)
Interest Expense / Debt = 6.31% (Interest Expense 100.3m / Debt 1.59b)
Taxrate = 27.69% (27.5m / 99.2m)
NOPAT = 147.2m (EBIT 203.6m * (1 - 27.69%))
Current Ratio = 1.64 (Total Current Assets 1.71b / Total Current Liabilities 1.04b)
Debt / Equity = 0.89 (Debt 1.59b / totalStockholderEquity, last quarter 1.78b)
Debt / EBITDA = 3.65 (Net Debt 1.31b / EBITDA 357.6m)
Debt / FCF = 3.33 (Net Debt 1.31b / FCF TTM 392.2m)
Total Stockholder Equity = 1.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.60% (Net Income 71.6m / Total Assets 4.34b)
RoE = 4.08% (Net Income TTM 71.6m / Total Stockholder Equity 1.75b)
RoCE = 6.72% (EBIT 203.6m / Capital Employed (Equity 1.75b + L.T.Debt 1.27b))
RoIC = 4.61% (NOPAT 147.2m / Invested Capital 3.20b)
WACC = 8.67% (E(3.81b)/V(5.40b) * Re(10.39%) + D(1.59b)/V(5.40b) * Rd(6.31%) * (1-Tc(0.28)))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.13 | Cagr: -0.89%
[DCF] Terminal Value 74.31% ; FCFF base≈392.2m ; Y1≈393.8m ; Y5≈417.2m
[DCF] Fair Price = 49.94 (EV 6.15b - Net Debt 1.31b = Equity 4.84b / Shares 97.0m; r=8.67% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.16 | # QB: 0
Revenue Correlation: -27.36 | Revenue CAGR: -1.76% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.30 | Chg30d=+0.97% | Revisions=-57% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=+1.03% | Revisions=-57% | Analysts=8
EPS current Year (2027-03-31): EPS=1.38 | Chg30d=+0.76% | Revisions=-67% | GrowthEPS=+12.9% | GrowthRev=+2.0%
EPS next Year (2028-03-31): EPS=1.62 | Chg30d=-1.59% | Revisions=-17% | GrowthEPS=+17.5% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: -75% (up=1, down=16)